For example, a CXCR4 antagonist Plerixafor (AMD3100), which can inhibit the secretion of VEGF-A from TAMs and lead to reduce tumor angiogenesis, has been used in clinical trials for treating solid tumors and children cancer (73). This evidence concerns the gene CXCR4 and neoplasm.